1-6 of 6
Robert L. Ilaria, Jr
Close
Sort by
Journal Articles

STAT5 signaling is required for the efficient induction and maintenance of CML in mice

Dan Ye, Nicholas Wolff, Li Li, Shumin Zhang, Robert L. Ilaria, Jr
Journal: Blood
Blood (2006) 107 (12): 4917–4925.
https://doi.org/10.1182/blood-2005-10-4110
Published: 2006
Journal Articles

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia

Nicholas C. Wolff, Darren R. Veach, William P. Tong, William G. Bornmann, Bayard Clarkson, Robert L. Ilaria, Jr
Journal: Blood
Blood (2005) 105 (10): 3995–4003.
https://doi.org/10.1182/blood-2004-09-3534
Published: 2005
Journal Articles

STAT5 and STAT5A Signaling Play an Important Role in the Pathophysiology of the CML-Like Myeloproliferative Disorder in Mice.

Dan Ye, MD, Li Li, MD, Robert L. Ilaria, Jr., MD
Journal: Blood
Blood (2004) 104 (11): 2959.
https://doi.org/10.1182/blood.V104.11.2959.2959
Published: 2004
Journal Articles

The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia

Brief Report
Nicholas C. Wolff, James A. Richardson, Merrill Egorin, Robert L. Ilaria, Jr
Journal: Blood
Blood (2003) 101 (12): 5010–5013.
https://doi.org/10.1182/blood-2002-10-3059
Published: 2003
Journal Articles

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571

Nicholas C. Wolff, Robert L. Ilaria, Jr
Journal: Blood
Blood (2001) 98 (9): 2808–2816.
https://doi.org/10.1182/blood.V98.9.2808
Published: 2001
Journal Articles

Dominant Negative Mutants Implicate STAT5 in Myeloid Cell Proliferation and Neutrophil Differentiation

Robert L. Ilaria, Jr, Robert G. Hawley, Richard A. Van Etten
Journal: Blood
Blood (1999) 93 (12): 4154–4166.
https://doi.org/10.1182/blood.V93.12.4154
Published: 1999